In the past week, TSHA stock has gone up by 1.27%, with a monthly gain of 15.56% and a quarterly surge of 71.91%. The volatility ratio for the week is 7.84%, and the volatility levels for the last 30 days are 7.31% for Taysha Gene Therapies Inc The simple moving average for the last 20 days is 10.56% for TSHA stock, with a simple moving average of 42.70% for the last 200 days.
Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?
TSHA has 36-month beta value of 1.02. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 176.26M, and currently, short sellers hold a 14.89% ratio of that float. The average trading volume of TSHA on June 03, 2025 was 3.20M shares.
TSHA) stock’s latest price update
The stock of Taysha Gene Therapies Inc (NASDAQ: TSHA) has increased by 2.77 when compared to last closing price of 2.71. Despite this, the company has experienced a 1.27% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-29 that Taysha Gene Therapies, Inc. achieved positive updated data from Part A of the phase 1/2 REVEAL study using TSHA-102 to treat patients with Rett Syndrome. Alignment gained with FDA on IND amendments to be submitted to begin pivotal part B study of TSHA-102 for the treatment of patients with Rett Syndrome. The global market for Rett Syndrome in the 7 major markets is expected to reach $441.5 million by 2035.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.
TSHA Trading at 42.60% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.53% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 1,333,333 shares at the price of $2.25 back on Jun 27 ’24. After this action, Manning Paul B now owns 1,333,333 shares of Taysha Gene Therapies Inc, valued at $2,999,999 using the latest closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -12.26 for the present operating margin
- 0.73 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -12.01. The total capital return value is set at -0.76. Equity return is now at value -159.34, with -59.56 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -4.88. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -1639.81.
Currently, EBITDA for the company is -87.95 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 68.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.35.
Conclusion
To put it simply, Taysha Gene Therapies Inc (TSHA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
